Parker Domnick Hunter to Manufacture Automated Bioprocessing Systems at UK Facility
The facility in Britley will now manufacture the company’s automated systems, enabling the company to better serve European markets and shorten the supply chain.
Bioprocessing solutions provider, Parker Domnick Hunter (a division of the Parker Hannifin corporation) has enhanced its manufacturing capabilities at its Britley site in the United Kingdom. The facility will now manufacture the company’s automated systems. This move enables the company to better serve European markets and shorten the supply chain.
Parker Domnick Hunter designs, supplies, and delivers single-use systems for pharmaceutical and biopharmaceutical manufacturing. This is the first time the company will be manufacturing automated systems in the UK, complementing existing production at its US site in Oxnard, California. European customers will have easier access to automated systems and specialist technical support.
The division at Britley will manufacture a range of automated systems to European standards, including the SciLog Filter and Dispense System, designed for bulk drug filter and dispense; the SciLog SciPure System, a GMP-ready system for tangential flow or normal flow filtration applications; and the SciLog SciFlex System, which is used for tangential flow and normal flow filtration applications, from discovery to pilot-scale production. Additional fabrication of stainless steel products used in the automated systems will be carried out at Parker Domnick Hunter’s fabrication unit in nearby Boldon.
In 2016, the company announced that it has installed a new ISO Class 7 clean room at the Birtley premises, which facilitated the production of single-use manifolds incorporating tubing, bioprocess containers, filters, sensors and other components for use in the bioprocessing industry.
Source: Parker Domnick Hunter
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
